Navigation Links
WorldHeart Signs Agreements for Next-Generation Minimally Invasive Blood Pump
Date:11/17/2009

SALT LAKE CITY, Nov. 17 /PRNewswire-FirstCall/ -- ("WorldHeart"; Nasdaq: WHRT) - World Heart Corporation (WorldHeart) announced today that it has finalized assignment and exclusive license agreements with LaunchPoint Technologies Inc., (LPT) Goleta, California, and Carnegie Mellon University (CMU), Pittsburgh, Pennsylvania for its next-generation minimally invasive blood pump, the MiVAD. The MiVAD(TM) is designed to provide partial cardiac support between 2-4 liters per minute to less sick heart failure patients than those served by existing full-support Left Ventricular Assist Devices (LVADs).

The MiVAD design is based on the Pediaflow(TM) LVAD design and intellectual property. The PediaFlow LVAD, a miniaturized implantable fully magnetically levitated blood pump, is intended for neonates and has evolved significantly through design and development. The latest version of the PediaFlow pump is approximately the size of a AA battery and was successfully evaluated in a multi-month animal trial this summer. The Pediaflow LVAD development has been led by the University of Pittsburgh, Pittsburgh, Pennsylvania and has been primarily funded by the National Heart, Lung and Blood Institute with supplemental funding and technology contributions from WorldHeart. WorldHeart, CMU and LPT are members of the development consortium. The work completed on this device is the foundation for the MiVAD. Additionally, the MiVAD will incorporate existing intellectual property as well as internal and external design features from the Levacor(TM) LVAD.

Mr. Alex Martin, WorldHeart's CEO, commented that, "while WorldHeart continues to focus on the clinical use and commercialization of the Levacor LVAD, these agreements allow WorldHeart to accelerate the development of the MiVAD and related technology in the area of miniaturization of magnetically levitated blood pumps".

Dr. Brad Paden, founder and CEO of LPT added that, "we are pleased that this breakthrough miniaturization technology will be integrated with WorldHeart's existing and complementary fully magnetically levitated blood pump platform to meet a new, large and promising clinical need".

About World Heart Corporation

WorldHeart is a developer of mechanical circulatory support systems in Salt Lake City, Utah with additional facilities in Oakland, California, USA and Herkenbosch, The Netherlands. WorldHeart's registered office is in Ottawa, Ontario, Canada.

Any forward-looking statements in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include all statements relating to the advancement of WorldHeart's clinical development programs, the potential clinical benefits of the Levacor LVAD, PediaFlow LVAD and MiVAD, and the growth of WorldHeart's overall business, as well as other statements that can be identified by the use of forward-looking language, such as "believes," "feels," "expects," "may," "will," "should," "seeks," "plans," "anticipates," or "intends" or the negative of those terms, or by discussions of strategy or intentions. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including without limitation: WorldHeart's need for additional capital in the future; risks in product development, regulatory approvals and market acceptance of and demand for WorldHeart's products; acquisition and commercialization of new technologies in the area of miniaturization of magnetically levitated blood pumps and successful development of the MiVAD; and other risks detailed in WorldHeart's filings with the U.S. Securities and Exchange Commission, including without limitation its Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2009, June 30, 2009 and September 30, 2009.

www.worldheart.com

SOURCE World Heart Corporation


'/>"/>
SOURCE World Heart Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
2. WorldHeart Receives US Clinical Study Approval for the Levacor(TM) VAD
3. WorldHeart Receives IRB Approval at First Center in the Levacor(TM) VAD BTT Clinical Trial
4. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
5. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
6. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
7. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
8. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
9. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science
10. Rosetta Genomics Signs Agreement With West Coast CLIA Certified Lab to Develop and Validate Tests Applying Companys MicroRNA Technology
11. Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... PUNE , Maharashtra, February 12, 2016 /PRNewswire/ ... Market research report titled Chronic Inflammation Global ... and a snapshot of the global clinical trials ... the clinical trials by Region, Country (G7 & ... End point status and reviews top companies involved ...
(Date:2/11/2016)... LONDON , Feb. 11, 2016 The ... current and future adoption patterns on the usage of ... include the following: - Timeframe of liquid ... types—CTCs, ctDNA, cfDNA and Evs—by organization type - Sample ... sample types: blood, saliva, stool, serum, and so on. ...
(Date:2/11/2016)... Feb. 11, 2016 PRO-DEX, INC. (NasdaqCM: PDEX) today ... December 31, 2015. The Company also filed its Quarterly Report ... 2016 with the Securities and Exchange Commission today. ... 2015 --> --> Net ... $2.6 million, or 95%, to $5.4 million from $2.8 million ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... Good news ... first in the area to offer AngioPlex™ Optical Coherence Tomography (OCT) Angiography, imaging ... as macular degeneration, diabetic retinopathy, and other vascular conditions. , In just a ...
(Date:2/13/2016)... ... 2016 , ... Many individuals looking to lead a healthy lifestyle have decreased ... IsoPasta by Isolator Fitness has delved into this niche allowing those giving up their ... IsoPasta has 30 grams of protein and only 7 grams of carbohydrates per ...
(Date:2/13/2016)... , ... February 13, 2016 , ... ... of Nursing with an in-kind gift of a VeinViewer® Vision vein finder ... they learn how to start an IV and draw blood, combining technology with ...
(Date:2/12/2016)... ... ... According to an article published February 4th on mySA, robotically ... hernia repairs throughout the United States. Commenting on this article, Beverly Hills hernia repair ... has not only been expected, but it seems to be a natural result of ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February 8, ...
Breaking Medicine News(10 mins):